Deals
Debt offerings decreased significantly in the pharmaceutical industry in H2 2021
The proportion of pharmaceutical companies hiring for cloud related positions rose to a year-high in August 2021, with 42.7% of the companies included in our analysis recruiting for at least one such position.
Debt offerings in the pharma sector have seen a decrease of 34.7% from H2 2020 to H2 2021, an analysis of GlobalData's deals database reveals.
Powered by
In the second half of 2021 the number of debt offerings decreased significantly by 34.7% from the same period in 2020.
This marks an acceleration in growth from the 65.7% decrease in deals that occurred in H1 2021 relative to the same period a year earlier.
During second half of 2021, debt offerings accounted for 5.4% of all deals taking place in the sector. This represents a decrease from the figure of 6.5% in second half of 2020.
GlobalData's deals database is a comprehensive repository that looks at mergers, acquisitions, venture financing, equity offerings, asset transactions, partnerships and debt offerings taking place daily between thousands of companies across the world.
The database details key deal information, such as deal summary, deal rationale, deal financials, parties involved, advisors and deal payment modes.
By tracking the proportion of various types of deals in each sector we can gauge which sectors are seeing growth and where others are struggling.
The highest value debt offering announced in 2021 (where the deal value was known), is the funds to be raised by Takeda Pharma in a public offering of 0.400% senior bonds due in 2031. The debt offering is set to be worth $2242.5 million.
The database states that the rationale behind this deal was as follows: "Takeda intends to use the proceeds primarily to prepay borrowings of USD1.7 billion that remain outstanding on a term loan incurred in connection with the acquisition of Shire plc in 2019 and which has an original maturity date of December 2025. The remaining bond issuance proceeds, will be used for the redemption of bonds or be deployed towards the working capital needs."
